Skip to main content
Erschienen in: Archives of Dermatological Research 10/2009

01.10.2009 | Mini Review

Behçet’s disease: an algorithmic approach to its treatment

verfasst von: Erkan Alpsoy, Ayse Akman

Erschienen in: Archives of Dermatological Research | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Behçet’s disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology with the clinical features of mucocutaneous lesions, ocular, vascular, articular, gastrointestinal, urogenital, pulmonary, and neurologic involvement. Mucocutaneous lesions figure prominently in the presentation and diagnosis, and may be considered the hallmarks of BD. Therefore, their recognition may permit earlier diagnosis and treatment. Although, the treatment has become much more effective in recent years, BD is still associated with severe morbidity and considerable mortality. The main aim of the treatment should be the prevention of irreversible organ damage. Therefore, close monitoring, early and appropriate treatment is mandatory to reduce morbidity and mortality. We reviewed the current state of knowledge regarding the therapeutic approaches for BD and designed a stepwise, symptom-based, algorithmic approach, mainly based on controlled studies and our clinical experience in this field to provide a rational framework for selecting the appropriate therapy along the various treatment choices.
Literatur
1.
Zurück zum Zitat Addy M, Carpenter R, Roberts WR (1976) Management of recurrent aphthous ulceration. A trial of chlorhexidine gel. Br Dent J 141:118–120PubMedCrossRef Addy M, Carpenter R, Roberts WR (1976) Management of recurrent aphthous ulceration. A trial of chlorhexidine gel. Br Dent J 141:118–120PubMedCrossRef
2.
Zurück zum Zitat Adler YD, Mansmann U, Zouboulis CC (2001) Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades–Behçet’s disease. Dermatology 203:322–324PubMedCrossRef Adler YD, Mansmann U, Zouboulis CC (2001) Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades–Behçet’s disease. Dermatology 203:322–324PubMedCrossRef
3.
Zurück zum Zitat Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E (2007) Relationship between periodontal findings and Behcet’s disease: a controlled study. J Clin Periodontol 34:485–491PubMedCrossRef Akman A, Kacaroglu H, Donmez L, Bacanli A, Alpsoy E (2007) Relationship between periodontal findings and Behcet’s disease: a controlled study. J Clin Periodontol 34:485–491PubMedCrossRef
4.
Zurück zum Zitat Akman A, Sallakci N, Kacaroglu H et al (2008) Relationship between periodontal findings and the TNF-alpha Gene 1031T/C polymorphism in Turkish patients with Behçet’s disease. J Eur Acad Dermatol Venereol 22(8):950–957PubMedCrossRef Akman A, Sallakci N, Kacaroglu H et al (2008) Relationship between periodontal findings and the TNF-alpha Gene 1031T/C polymorphism in Turkish patients with Behçet’s disease. J Eur Acad Dermatol Venereol 22(8):950–957PubMedCrossRef
5.
Zurück zum Zitat Aktulga E, Altac M, Muftuoglu A et al (1980) A double blind study of colchicine in Behcet’s disease. Haematologica 65:399–402PubMed Aktulga E, Altac M, Muftuoglu A et al (1980) A double blind study of colchicine in Behcet’s disease. Haematologica 65:399–402PubMed
6.
Zurück zum Zitat Alpsoy E (2005) Behçet’s disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol 23:532–539PubMed Alpsoy E (2005) Behçet’s disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol 23:532–539PubMed
7.
Zurück zum Zitat Alpsoy E, Akman A (2006) Treatment of Behçet’s disease. Therapy 3:139–151 Alpsoy E, Akman A (2006) Treatment of Behçet’s disease. Therapy 3:139–151
8.
Zurück zum Zitat Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E (1998) A randomized, controlled and blinded study of papulopustular lesions in Turkish Behcet’s patients. Int J Dermatol 37:839–843PubMedCrossRef Alpsoy E, Aktekin M, Er H, Durusoy C, Yilmaz E (1998) A randomized, controlled and blinded study of papulopustular lesions in Turkish Behcet’s patients. Int J Dermatol 37:839–843PubMedCrossRef
9.
Zurück zum Zitat Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B (2003) Review of the clinical manifestations’ chronology in 60 patients with Behçet’s disease. Dermatology 117:354–356CrossRef Alpsoy E, Donmez L, Bacanli A, Apaydin C, Butun B (2003) Review of the clinical manifestations’ chronology in 60 patients with Behçet’s disease. Dermatology 117:354–356CrossRef
10.
Zurück zum Zitat Alpsoy E, Donmez L, Onder M et al (2007) Clinical features and natural course of Behcet’s disease in 661 cases: a multicentre study. Br J Dermatol 157:901–906PubMedCrossRef Alpsoy E, Donmez L, Onder M et al (2007) Clinical features and natural course of Behcet’s disease in 661 cases: a multicentre study. Br J Dermatol 157:901–906PubMedCrossRef
11.
Zurück zum Zitat Alpsoy E, Durusoy C, Yilmaz E et al (2002) Interferon alpha-2a in the treatment of Behçet disease: a randomized, placebo-controlled and double blind study. Arch Dermatol 138:467–471PubMedCrossRef Alpsoy E, Durusoy C, Yilmaz E et al (2002) Interferon alpha-2a in the treatment of Behçet disease: a randomized, placebo-controlled and double blind study. Arch Dermatol 138:467–471PubMedCrossRef
12.
Zurück zum Zitat Alpsoy E, Er H, Durusoy C, Yilmaz E (1999) The use of sucralfate suspension in the treatment of oral and genital ulcerations of Behçet’s disease: a randomised, placebo-controlled and double-blind study. Arch Dermatol 135:529–532PubMedCrossRef Alpsoy E, Er H, Durusoy C, Yilmaz E (1999) The use of sucralfate suspension in the treatment of oral and genital ulcerations of Behçet’s disease: a randomised, placebo-controlled and double-blind study. Arch Dermatol 135:529–532PubMedCrossRef
13.
Zurück zum Zitat Alpsoy E, Zouboulis CC, Ehrlich CE (2007) Mucocutaneous lesions of Behçet’s disease. Yonsei Med J 48:573–585PubMedCrossRef Alpsoy E, Zouboulis CC, Ehrlich CE (2007) Mucocutaneous lesions of Behçet’s disease. Yonsei Med J 48:573–585PubMedCrossRef
14.
Zurück zum Zitat Al-Waiz MM, Sharquie KE, A-Qaissi MH, Hayani RK (2005) Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. Dermatol Online J 11(3):3PubMed Al-Waiz MM, Sharquie KE, A-Qaissi MH, Hayani RK (2005) Colchicine and benzathine penicillin in the treatment of Behcet disease: a case comparative study. Dermatol Online J 11(3):3PubMed
15.
Zurück zum Zitat Assaad-Khalil SH (1991) Low-dose cyclosporin in Behçet’s disease: follow-up controlled study with emphasis on extraocular manifestations and neuro-Behçet’s disease. In: O’Duffy JD, Kokmen E (eds) Behçet’s disease: basic and clinical aspects. Marcel Dekker, New York, pp 603–612 Assaad-Khalil SH (1991) Low-dose cyclosporin in Behçet’s disease: follow-up controlled study with emphasis on extraocular manifestations and neuro-Behçet’s disease. In: O’Duffy JD, Kokmen E (eds) Behçet’s disease: basic and clinical aspects. Marcel Dekker, New York, pp 603–612
16.
Zurück zum Zitat Azizlerli G, Kose AA, Sarica R et al (2003) Prevalence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol 42:803–806PubMedCrossRef Azizlerli G, Kose AA, Sarica R et al (2003) Prevalence of Behcet’s disease in Istanbul, Turkey. Int J Dermatol 42:803–806PubMedCrossRef
17.
Zurück zum Zitat Bacanli A, Yerebakan O, Parmaksizoglu B, Yilmaz E, Alpsoy E (2006) Topical granulocyte-colony stimulating factor for the treatment of oral and genital ulcers of patients with Behçet’s disease. J Eur Acad Dermatol Venereol 20:931–935PubMed Bacanli A, Yerebakan O, Parmaksizoglu B, Yilmaz E, Alpsoy E (2006) Topical granulocyte-colony stimulating factor for the treatment of oral and genital ulcers of patients with Behçet’s disease. J Eur Acad Dermatol Venereol 20:931–935PubMed
18.
Zurück zum Zitat Bang D (1997) Treatment of Behcet’s disease. Yonsei Med J 38:401–410PubMed Bang D (1997) Treatment of Behcet’s disease. Yonsei Med J 38:401–410PubMed
19.
Zurück zum Zitat BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome. Transplant Proc 20:136–143PubMed BenEzra D, Cohen E, Chajek T et al (1988) Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome. Transplant Proc 20:136–143PubMed
20.
Zurück zum Zitat Binnie WH, Curro FA, Khandwala A, Van Inwegan RG (1997) Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent 18:1116–1124PubMed Binnie WH, Curro FA, Khandwala A, Van Inwegan RG (1997) Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent 18:1116–1124PubMed
21.
Zurück zum Zitat Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I (1996) Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet’s disease. Dermatology 192:125–128PubMedCrossRef Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I (1996) Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet’s disease. Dermatology 192:125–128PubMedCrossRef
22.
Zurück zum Zitat Conklin RJ, Blasberg B (1991) Common inflammatory diseases of the mouth. Int J Dermatol 30:323–335PubMedCrossRef Conklin RJ, Blasberg B (1991) Common inflammatory diseases of the mouth. Int J Dermatol 30:323–335PubMedCrossRef
23.
Zurück zum Zitat Davatchi F, Shahram F, Chams H, Akbarian M (1999) Pulse cyclophosphamide (PCP) for ocular lesions of Behçet’s disease: double blind crossover study. Arthritis Rheum 42:S320 Davatchi F, Shahram F, Chams H, Akbarian M (1999) Pulse cyclophosphamide (PCP) for ocular lesions of Behçet’s disease: double blind crossover study. Arthritis Rheum 42:S320
24.
Zurück zum Zitat Davatchi F, Shahram F, Chams H et al (2003) High dose methotrexate for ocular lesions of Behçet’s disease. Preliminary short-term results. Adv Exp Med Biol 528:579–584PubMedCrossRef Davatchi F, Shahram F, Chams H et al (2003) High dose methotrexate for ocular lesions of Behçet’s disease. Preliminary short-term results. Adv Exp Med Biol 528:579–584PubMedCrossRef
25.
Zurück zum Zitat Elidan J, Cohen E, Levi H, BenEzra D (1991) Effect of cyclosporine A on the hearing loss in Behçet’s disease. Ann Otol Rhinol Laryngol 100:464–468PubMed Elidan J, Cohen E, Levi H, BenEzra D (1991) Effect of cyclosporine A on the hearing loss in Behçet’s disease. Ann Otol Rhinol Laryngol 100:464–468PubMed
26.
Zurück zum Zitat Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N (2007) Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J 13:1PubMed Gorsky M, Epstein J, Rabenstein S, Elishoov H, Yarom N (2007) Topical minocycline and tetracycline rinses in treatment of recurrent aphthous stomatitis: a randomized cross-over study. Dermatol Online J 13:1PubMed
27.
Zurück zum Zitat Graykowski EA, Kingman A (1978) Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol 7:376–382PubMedCrossRef Graykowski EA, Kingman A (1978) Double-blind trial of tetracycline in recurrent aphthous ulceration. J Oral Pathol 7:376–382PubMedCrossRef
28.
Zurück zum Zitat Greer RO Jr, Lindenmuth JE, Juarez T, Khandwala A (1993) A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg 51:243–248PubMedCrossRef Greer RO Jr, Lindenmuth JE, Juarez T, Khandwala A (1993) A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg 51:243–248PubMedCrossRef
29.
Zurück zum Zitat Gurler A, Boyvat A, Tursen U (1997) Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J 38:423–427PubMed Gurler A, Boyvat A, Tursen U (1997) Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J 38:423–427PubMed
30.
Zurück zum Zitat Hamuryudan V, Mat C, Saip S et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443–450PubMed Hamuryudan V, Mat C, Saip S et al (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443–450PubMed
31.
Zurück zum Zitat Hamuryudan V, Moral F, Yurdakul S et al (1994) Systemic interferon alpha 2b treatment in Behçet’s syndrome. J Rheumatol 21:1098–1100PubMed Hamuryudan V, Moral F, Yurdakul S et al (1994) Systemic interferon alpha 2b treatment in Behçet’s syndrome. J Rheumatol 21:1098–1100PubMed
32.
Zurück zum Zitat Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 67:1656–1662PubMedCrossRef Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 67:1656–1662PubMedCrossRef
33.
Zurück zum Zitat Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet’s disease. J Am Acad Dermatol 24:973–978PubMedCrossRef Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF (1991) Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behçet’s disease. J Am Acad Dermatol 24:973–978PubMedCrossRef
34.
Zurück zum Zitat Kikuchi H, Aramaki K, Hirohata S (2003) Low dose MTX for progressive neuro-Behçet’s disease. A follow-up study for 4 years. Adv Exp Med Biol 528:575–578PubMedCrossRef Kikuchi H, Aramaki K, Hirohata S (2003) Low dose MTX for progressive neuro-Behçet’s disease. A follow-up study for 4 years. Adv Exp Med Biol 528:575–578PubMedCrossRef
35.
Zurück zum Zitat Kerr AR, Drexel CA, Spielman AI (2003) The efficacy and safety of 50 mg penicillin G potassium troches for recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96:685–694PubMedCrossRef Kerr AR, Drexel CA, Spielman AI (2003) The efficacy and safety of 50 mg penicillin G potassium troches for recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 96:685–694PubMedCrossRef
36.
Zurück zum Zitat Kötter I, Günaydin I, Batra M et al (2006) CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications-results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482–486PubMedCrossRef Kötter I, Günaydin I, Batra M et al (2006) CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications-results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482–486PubMedCrossRef
37.
Zurück zum Zitat Kötter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon-alpha2a for the treatment of Behçet’s disease with sight-threatening posterior or panuveitis. Br J Ophthalmol 87:423–431PubMedCrossRef Kötter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon-alpha2a for the treatment of Behçet’s disease with sight-threatening posterior or panuveitis. Br J Ophthalmol 87:423–431PubMedCrossRef
38.
Zurück zum Zitat Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRef Kural-Seyahi E, Fresko I, Seyahi N et al (2003) The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 82:60–76CrossRef
39.
Zurück zum Zitat Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet 20:1093–1096CrossRef Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet 20:1093–1096CrossRef
40.
Zurück zum Zitat Mat C, Yurdakul S, Ozyazgan Y, Uysal S, Uysal O, Yazıcı H (2006) A double-blind trial of depot corticosteroids in Behçet’s syndrome. Rheumatology (Oxford) 45:348–352CrossRef Mat C, Yurdakul S, Ozyazgan Y, Uysal S, Uysal O, Yazıcı H (2006) A double-blind trial of depot corticosteroids in Behçet’s syndrome. Rheumatology (Oxford) 45:348–352CrossRef
41.
Zurück zum Zitat Matsuda T, Ohno S, Hirohata S et al (2003) Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study. Drugs RD 4:19–28CrossRef Matsuda T, Ohno S, Hirohata S et al (2003) Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study. Drugs RD 4:19–28CrossRef
42.
Zurück zum Zitat Meiller TF, Kutcher MJ, Overholser CD, Niehaus C, DePaola LG, Siegel MA (1991) Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg Oral Med Oral Pathol 72:425–429PubMedCrossRef Meiller TF, Kutcher MJ, Overholser CD, Niehaus C, DePaola LG, Siegel MA (1991) Effect of an antimicrobial mouthrinse on recurrent aphthous ulcerations. Oral Surg Oral Med Oral Pathol 72:425–429PubMedCrossRef
43.
Zurück zum Zitat Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 32:98–105PubMed Melikoglu M, Fresko I, Mat C et al (2005) Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol 32:98–105PubMed
44.
Zurück zum Zitat Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21(6):824–825PubMedCrossRef Mushtaq B, Saeed T, Situnayake RD, Murray PI (2007) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye 21(6):824–825PubMedCrossRef
45.
Zurück zum Zitat Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A (2009) Long-term control of cystoid macular oedema in noninfectious uveitis with mycophenolate mofetil. Int Ophthalmol 29:127–133PubMedCrossRef Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A (2009) Long-term control of cystoid macular oedema in noninfectious uveitis with mycophenolate mofetil. Int Ophthalmol 29:127–133PubMedCrossRef
46.
Zurück zum Zitat Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368PubMed Ohno S, Nakamura S, Hori S et al (2004) Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368PubMed
47.
Zurück zum Zitat Ozyazgan Y, Yurdakul S, Yazici H et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243PubMedCrossRef Ozyazgan Y, Yurdakul S, Yazici H et al (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br J Ophthalmol 76:241–243PubMedCrossRef
48.
Zurück zum Zitat Sakane T, Takeno M, Suziki N, Inaba G (1999) Behcet’s disease. N Engl J Med 341:1284–1291PubMedCrossRef Sakane T, Takeno M, Suziki N, Inaba G (1999) Behcet’s disease. N Engl J Med 341:1284–1291PubMedCrossRef
49.
Zurück zum Zitat Saxen MA, Ambrosius WT, Rehemtula al KF, Russell AL, Eckert GJ (1997) Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:356–361PubMedCrossRef Saxen MA, Ambrosius WT, Rehemtula al KF, Russell AL, Eckert GJ (1997) Sustained relief of oral aphthous ulcer pain from topical diclofenac in hyaluronan: a randomized, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84:356–361PubMedCrossRef
50.
Zurück zum Zitat Sfikakis PP, Kaklamanis PH, Elezoglou A et al (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades–Behçet disease. Ann Intern Med 140:404–406PubMed Sfikakis PP, Kaklamanis PH, Elezoglou A et al (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades–Behçet disease. Ann Intern Med 140:404–406PubMed
51.
Zurück zum Zitat Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46(5):736–741CrossRef Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet’s disease—review and basis for recommendations. Rheumatology (Oxford) 46(5):736–741CrossRef
52.
Zurück zum Zitat Sharquie KE, Najim RA, Abu-Raghif AR (2002) Dapsone in Behcet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 29:267–279PubMed Sharquie KE, Najim RA, Abu-Raghif AR (2002) Dapsone in Behcet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 29:267–279PubMed
53.
Zurück zum Zitat Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK (2006) Oral zinc sulfate in the treatment of Behcet’s disease: a double blind cross-over study. J Dermatol 33:541–546PubMed Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK (2006) Oral zinc sulfate in the treatment of Behcet’s disease: a double blind cross-over study. J Dermatol 33:541–546PubMed
54.
Zurück zum Zitat Siva A, Altintas A, Saip S (2004) Behçet’s syndrome and the nervous system. Curr Opin Neurol 17:347–357PubMedCrossRef Siva A, Altintas A, Saip S (2004) Behçet’s syndrome and the nervous system. Curr Opin Neurol 17:347–357PubMedCrossRef
55.
Zurück zum Zitat Skaare AB, Herlofson BB, Barkvoll P (1996) Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). J Clin Periodontol 23:778–781PubMedCrossRef Skaare AB, Herlofson BB, Barkvoll P (1996) Mouthrinses containing triclosan reduce the incidence of recurrent aphthous ulcers (RAU). J Clin Periodontol 23:778–781PubMedCrossRef
56.
Zurück zum Zitat Suda H (1999) Low-dose weekly methotrexate therapy for progressive neuro-Behçet’s disease. Nihon Rinsho Meneki Gakkai Kaishi 22:13–22PubMed Suda H (1999) Low-dose weekly methotrexate therapy for progressive neuro-Behçet’s disease. Nihon Rinsho Meneki Gakkai Kaishi 22:13–22PubMed
57.
Zurück zum Zitat Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695PubMedCrossRef Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695PubMedCrossRef
58.
Zurück zum Zitat Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease. An open-label trial. Arthritis Rheum 52:2478–2484PubMedCrossRef Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitis that is refractory to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease. An open-label trial. Arthritis Rheum 52:2478–2484PubMedCrossRef
59.
Zurück zum Zitat Verity DH, Wallace GR, Seed PT et al (1998) Soluble adhesion molecules in Behcet’s disease. Ocul Immunol Inflamm 6:81–92PubMedCrossRef Verity DH, Wallace GR, Seed PT et al (1998) Soluble adhesion molecules in Behcet’s disease. Ocul Immunol Inflamm 6:81–92PubMedCrossRef
60.
Zurück zum Zitat Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 322:281–285PubMed Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med 322:281–285PubMed
61.
62.
Zurück zum Zitat Yurdakul S, Mat C, Tuzun Y et al (2001) A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum 44:2686–2692PubMedCrossRef Yurdakul S, Mat C, Tuzun Y et al (2001) A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum 44:2686–2692PubMedCrossRef
63.
Zurück zum Zitat Zouboulis CC, Kötter I, Djawari D et al (1997) Epidemiological features of Adamantiades–Behcet’s disease in Germany and in Europe. Yonsei Med J 38:411–422PubMed Zouboulis CC, Kötter I, Djawari D et al (1997) Epidemiological features of Adamantiades–Behcet’s disease in Germany and in Europe. Yonsei Med J 38:411–422PubMed
Metadaten
Titel
Behçet’s disease: an algorithmic approach to its treatment
verfasst von
Erkan Alpsoy
Ayse Akman
Publikationsdatum
01.10.2009
Verlag
Springer-Verlag
Erschienen in
Archives of Dermatological Research / Ausgabe 10/2009
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-009-0990-2

Weitere Artikel der Ausgabe 10/2009

Archives of Dermatological Research 10/2009 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.